WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device
company focused on the treatment and management of the neurological
complications of diabetes, today previewed its unaudited financial
highlights for the fourth quarter ended December 31, 2013.
Revenue in the fourth quarter of 2013 was approximately $1.4 million.
This represented the second consecutive quarter of sequential growth
from $1.3 million revenue reported for the third quarter of 2013 and
$1.2 million revenue reported for the second quarter of 2013. Revenue
for the full year 2013 was approximately $5.3 million. The Company's
cash usage during the fourth quarter was approximately $1.3 million and
NeuroMetrix ended the year with approximately $9.2 million in cash
resources.
Later today, Shai N. Gozani M.D., Ph.D., President and Chief Executive
Officer, is scheduled to speak at the 7th Annual OneMedForum
at The Westin San Francisco Market Street, San Francisco, CA. Dr. Gozani
intends to provide an update on the Company's business activities. The
presentation is scheduled for 10:50 am (Pacific Time), 1:50 pm (Eastern
Time). A live audio webcast will be available on the investor relations
section of the corporate website - www.neurometrix.com.
The Company is scheduled to release its financial results for the fourth
quarter and full year 2013 and to host an earnings call on February 13,
2014.
About NeuroMetrix
NeuroMetrix is a medical device company that develops and markets home
use and point-of-care devices for the treatment and management of
chronic pain, peripheral neuropathies, and associated neurological
disorders. The Company is presently focused on diabetic neuropathies,
which affect over 50% of people with diabetes. If left untreated,
diabetic neuropathies trigger foot ulcers that may require amputation
and cause disabling chronic pain. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company markets the SENSUS™ Pain Management System for
treating chronic pain, focusing on physicians managing patients with
painful diabetic neuropathy. The company also markets the DPNCheck® device,
which is a rapid, accurate, and quantitative point-of-care test for
diabetic neuropathy. This product is used to detect diabetic neuropathy
at an early stage and to guide treatment. For more information, please
visit www.neurometrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
www.neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
